NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 Antibody

What is NDUFB10 and what role does it play in mitochondrial function?

NDUFB10, also known as PDSW, is a crucial component of the mitochondrial respiratory chain complex I (NADH dehydrogenase). This 22kDa protein is involved in the electron transfer from NADH to the respiratory chain, with ubiquinone serving as the immediate electron acceptor for the enzyme . NDUFB10 is particularly important in mitochondrial respiratory chain complex I assembly and is located in the mitochondrial inner membrane .

How do researchers distinguish between various NADH dehydrogenase subunit antibodies?

Researchers must carefully distinguish between antibodies targeting different subunits of the NADH dehydrogenase complex, as these subunits have distinct functions and localizations. For example, NDUFB10 (a beta subcomplex subunit) differs significantly from NDUFA10 (an alpha subcomplex subunit) despite their similar nomenclature .

When selecting an antibody, researchers should verify:

• The exact target subunit (e.g., NDUFB10 versus NDUFA10)

• Species reactivity (human, mouse, rat, etc.)

• Applications validated (Western blot, immunohistochemistry, immunofluorescence)

• Clonality (monoclonal versus polyclonal)

• Host species and isotype

For instance, commercially available NDUFB10 antibodies include mouse monoclonal (clone OTI4F1) with reactivity to human, canine, rat, monkey, and mouse samples, and rabbit polyclonal antibodies with varying species reactivity profiles .

What are the validated applications for NDUFB10 antibodies in mitochondrial research?

NDUFB10 antibodies have been validated for multiple research applications, with varying degrees of effectiveness depending on the specific antibody:

Most NDUFB10 antibodies show robust performance in Western blot analysis, making this the preferred method for initial validation of antibody specificity .

What methodological approaches should be used to validate NDUFB10 antibody specificity?

Given the importance of antibody specificity in mitochondrial research, multiple validation approaches should be employed:

• Positive and negative controls: Use tissues/cells known to express NDUFB10 versus those with confirmed knockdown or knockout. Mitochondria-rich tissues such as heart, kidney, and liver typically show strong NDUFB10 expression.

• Knockout/knockdown validation: The most stringent validation involves testing the antibody on samples where the target has been depleted through genetic approaches (CRISPR-Cas9, siRNA). The absence or significant reduction of signal confirms specificity.

• Preabsorption test: Pre-incubate the antibody with purified NDUFB10 protein before staining to block specific binding sites. Loss of signal indicates specificity.

• Multiple antibody confirmation: Use two or more antibodies targeting different epitopes of NDUFB10 to confirm consistent localization patterns.

• Mass spectrometry validation: For immunoprecipitation applications, confirm pulled-down proteins via mass spectrometry to verify target identity.

• Cross-reactivity assessment: Test against related NADH dehydrogenase subunits, particularly those with similar molecular weights, to ensure specificity .

How can researchers optimize antigen retrieval for NDUFB10 immunohistochemistry?

Successful immunohistochemical detection of NDUFB10 often requires optimization of antigen retrieval techniques to expose epitopes masked during fixation:

• Heat-mediated antigen retrieval: This is the most effective method for NDUFB10 detection in formalin-fixed paraffin-embedded (FFPE) tissues. Citrate buffer (pH 6.0) has shown superior results compared to other buffers for most NDUFB10 antibodies .

• Retrieval protocol optimization:

  • Heat samples to 95-98°C in retrieval buffer for 15-20 minutes

  • Allow gradual cooling to room temperature for 20 minutes

  • Wash thoroughly in PBS before proceeding with blocking steps

• Enzymatic retrieval alternative: Some tissues may benefit from proteinase K treatment (10 μg/ml for 10-15 minutes at room temperature) instead of heat-mediated retrieval, though this is less commonly effective for NDUFB10.

• Fixation considerations: Overfixation significantly impacts NDUFB10 detection. Limit fixation in 10% neutral-buffered formalin to 24 hours maximum, and consider using Bouin's fixative for tissues with high fat content.

• Section thickness: 4-5 μm sections typically yield optimal results for NDUFB10 immunostaining .

What are the considerations for co-immunoprecipitation studies involving NDUFB10?

When investigating protein-protein interactions involving NDUFB10:

• Mitochondrial extraction quality: Since NDUFB10 is a mitochondrial protein, extraction methods must preserve the integrity of protein complexes while effectively solubilizing membrane-bound proteins.

• Crosslinking considerations: Due to the transient nature of some complex I assembly intermediates, consider using mild crosslinking agents (0.5-1% formaldehyde for 10 minutes) before extraction.

• Lysis buffer optimization: Standard RIPA buffer often disrupts mitochondrial complexes. Instead, use gentler buffers containing:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% Digitonin or 1% n-Dodecyl β-D-maltoside (DDM)

  • Protease inhibitor cocktail

• Antibody binding conditions: For optimal results, perform immunoprecipitation at 4°C overnight using 1-5 μg of antibody per 500 μg of protein lysate .

• Controls: Always include an isotype control antibody to assess non-specific binding, and a portion of the input lysate to confirm target protein presence.

How can NDUFB10 antibodies contribute to understanding mitochondrial disorders?

NDUFB10 antibodies serve as valuable tools for investigating various mitochondrial disorders, particularly those involving complex I dysfunction:

• Diagnostic applications: While not used diagnostically in clinical settings, NDUFB10 antibodies can help characterize mitochondrial abnormalities in research samples from patients with suspected mitochondrial disorders.

• Complex I assembly studies: NDUFB10 antibodies can detect alterations in complex I assembly patterns in patient samples, revealing whether mutations in other complex I subunits affect NDUFB10 incorporation.

• Comparison with other complex I subunits: Using antibody panels against multiple complex I subunits (including NDUFB10) can provide insights into assembly defects versus stability issues.

• Therapeutic response monitoring: In experimental treatments aimed at improving mitochondrial function, NDUFB10 antibodies can help assess changes in complex I integrity.

Current research indicates that deficiencies in complex I subunits have been associated with neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, bipolar disorder, and schizophrenia . While the focus has been primarily on catalytic subunits, accessory subunits like NDUFB10 may play important roles in disease pathogenesis through their effects on complex assembly and stability.

What methodological approaches are recommended for investigating NDUFB10 in neurodegenerative disease models?

When studying NDUFB10 in the context of neurodegenerative diseases:

• Tissue-specific considerations: Optimize protocols for neural tissues, which often require different processing than other tissues:

  • For immunohistochemistry: Use shorter fixation times (6-12 hours) and gentler permeabilization

  • For Western blot: Use specialized extraction buffers that maintain mitochondrial protein integrity while effectively lysing neural cells

• Co-localization studies: Combine NDUFB10 antibodies with markers for:

  • Mitochondrial dynamics (e.g., MFN2, DRP1)

  • Oxidative stress (e.g., 8-OHdG, 3-nitrotyrosine)

  • Neuronal/glial markers (e.g., NeuN, GFAP)

• Functional correlation: Correlate NDUFB10 expression/localization with functional measures:

  • Complex I activity assays

  • ROS production measurements

  • ATP synthesis capacity

• Animal model selection: Choose models relevant to the specific neurodegenerative condition being studied, with consideration for species differences in NDUFB10 sequence and expression levels .

How can researchers troubleshoot weak or absent signals when using NDUFB10 antibodies?

When facing detection challenges with NDUFB10 antibodies:

• Sample preparation optimization:

  • Ensure complete mitochondrial protein extraction using specialized buffers

  • For Western blot, avoid boiling samples (heat to 70°C for 10 minutes instead)

  • Use fresh samples whenever possible, as freeze-thaw cycles can degrade mitochondrial proteins

• Antibody concentration adjustment:

  • For Western blot: Try concentrations ranging from 1:250 to 1:1000

  • For IHC/IF: Begin with higher concentrations (1:50) and titrate as needed

  • For IP applications: Increase antibody amount to 5-10 μg per reaction

• Signal enhancement strategies:

  • For Western blot: Use enhanced chemiluminescence (ECL) substrates optimized for low-abundance proteins

  • For IHC/IF: Implement tyramide signal amplification (TSA) or polymer-based detection systems

  • Consider extended primary antibody incubation (overnight at 4°C)

• Epitope accessibility improvements:

  • Try alternative antigen retrieval methods (e.g., EDTA buffer pH 8.0)

  • Increase permeabilization time/concentration for IF applications

  • Test different fixation methods if possible .

What are the critical factors affecting specificity in multiplexed immunofluorescence studies with NDUFB10 antibodies?

For researchers conducting multiplexed studies incorporating NDUFB10 detection:

• Antibody selection criteria:

  • Choose primary antibodies raised in different host species to avoid cross-reactivity

  • Verify that secondary antibodies have been cross-adsorbed against other species

  • Consider directly conjugated primary antibodies for key targets

• Spectral overlap management:

  • Select fluorophores with minimal spectral overlap

  • Always include single-stained controls to establish proper compensation settings

  • Consider sequential rather than simultaneous detection for closely overlapping signals

• Order of antibody application:

  • Apply higher-affinity antibodies first in sequential protocols

  • When using antibodies from the same species, employ blocking strategies between rounds

• Blocking optimization:

  • Use species-specific serum matching secondary antibodies (5-10%)

  • Consider specialized blocking reagents for endogenous biotin/avidin or Fc receptors

  • Implement longer blocking times (2+ hours) for challenging tissues

• Data validation approaches:

  • Always compare multiplexed results with single-antibody controls

  • Validate co-localization findings with super-resolution microscopy if available

  • Consider orthogonal validation with proximity ligation assays for protein interaction claims .

How can researchers utilize NDUFB10 antibodies to study mitochondrial complex I assembly dynamics?

NDUFB10 antibodies offer valuable insights into complex I assembly processes:

• Assembly intermediate analysis:

  • Use blue native PAGE followed by Western blotting with NDUFB10 antibodies to identify assembly intermediates

  • Compare patterns between control and experimental conditions (e.g., mtDNA depletion, oxidative stress)

  • Correlate with other complex I subunits to map assembly sequence

• Pulse-chase experiments:

  • Combine metabolic labeling with immunoprecipitation using NDUFB10 antibodies to track newly synthesized subunit incorporation

  • Determine half-life and stability of NDUFB10 within complex I under various conditions

• Super-resolution microscopy applications:

  • Visualize submitochondrial distribution of NDUFB10 during various stages of mitochondrial dynamics

  • Quantify co-localization coefficients with other complex I subunits or assembly factors

  • Track changes in distribution patterns after mitochondrial stress

• Interaction with assembly factors:

  • Use NDUFB10 antibodies in proximity ligation assays to detect interactions with known assembly factors

  • Compare interaction profiles across different cell types and disease models .

What methodological considerations apply when using NDUFB10 antibodies to investigate post-translational modifications?

When investigating post-translational modifications (PTMs) of NDUFB10:

• Sample preparation to preserve PTMs:

  • Include appropriate phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in lysis buffers

  • For detection of oxidative modifications, include reducing agents or alkylating agents depending on the PTM of interest

  • Consider subcellular fractionation to enrich for mitochondrial proteins prior to analysis

• PTM-specific antibody selection:

  • Use antibodies specifically recognizing NDUFB10 with the PTM of interest (if available)

  • Alternatively, immunoprecipitate with NDUFB10 antibodies and blot with PTM-specific antibodies

  • For comprehensive PTM profiling, consider mass spectrometry analysis of immunoprecipitated NDUFB10

• Validation approaches:

  • Compare PTM status across normal and pathological conditions

  • Use site-directed mutagenesis to confirm functional relevance of identified PTM sites

  • Correlate PTM status with complex I activity and assembly state

• Quantification methods:

  • Use ratiometric approaches comparing modified to total NDUFB10

  • Implement internal loading controls for accurate comparisons across samples

  • Consider multiplexed detection systems for simultaneous analysis of multiple PTMs .

How should researchers address species differences when selecting NDUFB10 antibodies?

NDUFB10 shows varying degrees of conservation across species, necessitating careful antibody selection:

When working with non-human species:

• Epitope sequence verification:

  • Check if the antibody's epitope region is conserved in your species of interest

  • Request sequence information from manufacturers if not provided

• Validation requirements:

  • Always perform preliminary validation in your species of interest

  • Include appropriate positive controls from well-validated species

  • Consider testing multiple antibodies targeting different epitopes

• Application-specific considerations:

  • For less conserved species, Western blot typically offers higher success rates than IHC/IF

  • Adjust antibody concentrations upward when working with less conserved species

  • Optimize blocking conditions to minimize background in cross-species applications .